July 7, 2009 - CanBas Co., Ltd. (Numazu, Shizuoka, “CanBas”) and Takeda Pharmaceutical Company Limited (Osaka, “Takeda”) together with Takeda’s wholly-owned subsidiary Millennium: The Takeda Oncology Company (Cambridge, MA, “Millennium”) announced the advancement of CBP501 into Phase II clinical trials for the treatment of patients with non-small cell lung cancer (NSCLC). Current pre-clinical data suggest that CBP501 has the potential to induce cancer cell death through a mechanism of action that blocks the ability of cancer cells to transition through the cell cycle. Data from a previous Phase I study indicate that CBP501 may enhance anti-cancer cytotoxic activity when combined with selected chemotherapeutic drugs.
CanBas and Takeda signed a collaboration agreement in March 2007 for the development of investigational compounds to treat patients with cancer, including CBP501 and its backup compounds discovered by CanBas. Under the terms of this agreement, the worldwide exclusive rights for development, manufacturing and marketing have been granted to Takeda, while in the U.S. the development and promotion are jointly conducted by both companies. Millennium will work with CanBas to advance global development expeditiously. In November 2008, the companies initiated a Phase II trial of CBP501 in malignant pleural mesothelioma... CanBas' Press Release - Millennium's Press Release - Takeda's Press Release -
Blog Archive
-
▼
2009
(26)
-
▼
July
(10)
- Weinmann : MEDUMAT Transport offers multi-faceted ...
- CanBas and The Takeda Oncology Company (Millennium...
- Allos Therapeutics Completes Enrollment in Randomi...
- Endocyte : data on EC145 at the IASLC 13th World C...
- Boehringer Ingelheim and DxS : agreement for a com...
- Kai Sensors : FDA Clearance for its Wireless, Non-...
- Osmetech : FDA clears its Cystic Fibrosis Genotypi...
- Alnara Pharmaceuticals Licenses Worldwide Rights t...
- YM BioSciences : DAIICHI-SANKYO ENROLLS FIRST PATI...
- bitop AG and Activaero : collaboration on clinical...
-
▼
July
(10)
Jul 25, 2009
CanBas and The Takeda Oncology Company (Millennium) : CBP501 Enters Phase II Trials for the Treatment of Non-Small Cell Lung Cancer
Libellés :
CanBas,
Lung Cancer,
Millennium,
Takeda